Centessa Pharmaceuticals Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
77
- Stock Symbol
-
260
- Investments
-
10
- Share Price
-
$11.85
- (As of Thursday Closing)
Centessa Pharmaceuticals General Information
Description
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
Contact Information
Website
www.centessa.comCorporate Office
- 3rd Floor 1 Ashley Road
- Altrincham WA14 2DT
- England, United Kingdom
Corporate Office
- 3rd Floor 1 Ashley Road
- Altrincham WA14 2DT
- England, United Kingdom
Centessa Pharmaceuticals Stock Performance
As of 17-Apr-2025, Centessa Pharmaceuticals’s stock price is $11.85. Its current market cap is $1.64B with 133M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.85 | $11.52 | $7.56 - $18.66 | $1.64B | 133M | -$2.06 |
Centessa Pharmaceuticals Financials Summary
As of 31-Dec-2024, Centessa Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,774,683 | 1,774,683 | 579,291 | (83,395) |
| Revenue | 0 | 0 | 6,853 | 0 |
| EBITDA | (235,897) | (235,897) | (175,901) | (209,790) |
| Net Income | (235,757) | (235,757) | (151,085) | (216,207) |
| Total Assets | 576,798 | 576,798 | 360,246 | 444,307 |
| Total Debt | 117,226 | 117,226 | 84,588 | 69,800 |
Centessa Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Centessa Pharmaceuticals Comparisons
Industry
Financing
Details
Centessa Pharmaceuticals Competitors (3)
One of Centessa Pharmaceuticals’s 3 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Synlogic | Formerly VC-backed | Cambridge, MA | ||||
| BridgeBio Pharma | Formerly VC-backed | Palo Alto, CA |
Centessa Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Centessa Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Centessa Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Centessa Pharmaceuticals Acquisitions (10)
Centessa Pharmaceuticals’s most recent deal was a Merger/Acquisition with Morphogen-IX. The deal was made on 23-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Morphogen-IX | 23-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Capella BioScience | 16-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Inexia | 16-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Orexia | 16-Feb-2021 | Merger/Acquisition | Pharmaceuticals | ||
| PearlRiver Bio | 16-Feb-2021 | Merger/Acquisition | Drug Discovery |
Centessa Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated April, 04, 2023
34.66 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile
Pharmaceuticals
Industry
of 905
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Centessa Pharmaceuticals Exits (1)
Centessa Pharmaceuticals’s most recent exit was on 01-Jan-2021 from Pega-One. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pega-One | 01-Jan-2021 | Completed |
|
Centessa Pharmaceuticals Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Inexia | London, United Kingdom | 2018 | |
| Orexia | London, United Kingdom | 2018 | |
| Morphogen-IX | Cambridge, United Kingdom | 2015 | |
| Z Factor | Cambridge, United Kingdom | 2015 | |
| ApcinteX | London, United Kingdom | 2014 |
Centessa Pharmaceuticals FAQs
-
When was Centessa Pharmaceuticals founded?
Centessa Pharmaceuticals was founded in 2019.
-
Where is Centessa Pharmaceuticals headquartered?
Centessa Pharmaceuticals is headquartered in Altrincham, United Kingdom.
-
What is the size of Centessa Pharmaceuticals?
Centessa Pharmaceuticals has 77 total employees.
-
What industry is Centessa Pharmaceuticals in?
Centessa Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Centessa Pharmaceuticals a private or public company?
Centessa Pharmaceuticals is a Public company.
-
What is Centessa Pharmaceuticals’s stock symbol?
The ticker symbol for Centessa Pharmaceuticals is 260.
-
What is the current stock price of Centessa Pharmaceuticals?
As of 17-Apr-2025 the stock price of Centessa Pharmaceuticals is $11.85.
-
What is the current market cap of Centessa Pharmaceuticals?
The current market capitalization of Centessa Pharmaceuticals is $1.64B.
-
Who are Centessa Pharmaceuticals’s competitors?
ORIC Pharmaceuticals, Synlogic, and BridgeBio Pharma are competitors of Centessa Pharmaceuticals.
-
What is Centessa Pharmaceuticals’s annual earnings per share (EPS)?
Centessa Pharmaceuticals’s EPS for 12 months was -$2.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
